Pure Global
NCT06364176

Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.

Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis
University of Kansas Medical Center·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Cystic Fibrosis
Drug/Device/Intervention
Losartan
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
University of Kansas Medical Center
Location
Kansas City, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
May 01, 2024
End date
Oct 01, 2027
Enrollment
42 participants
Primary outcome

Sweat chloride

Summary

The goal of this clinical trial is to test use of losartan in those with cystic fibrosis (CF)
 on modulator therapy. The main question it aims to answer is if treatment with losartan
 improves response of the CF transmembrane conductance regulator (CFTR) channel to modulator
 therapy.
 
 Participants will be asked take losartan or placebo for twelve weeks and will have changes in
 sweat chloride levels measured as a marker of CFTR function.

ICD-10 classifications
Cystic fibrosisCystic fibrosis, unspecifiedCystic fibrosis with other manifestationsCystic fibrosis with pulmonary manifestationsCystic fibrosis with intestinal manifestations
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06364176
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06364176 through Pure Global AI's free database. This Phase 2 trial is sponsored by University of Kansas Medical Center and is currently Not yet recruiting. The study focuses on Cystic Fibrosis. Target enrollment is 42 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.